These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
794 related articles for article (PubMed ID: 25778307)
21. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. Di Nicolantonio F; Martini M; Molinari F; Sartore-Bianchi A; Arena S; Saletti P; De Dosso S; Mazzucchelli L; Frattini M; Siena S; Bardelli A J Clin Oncol; 2008 Dec; 26(35):5705-12. PubMed ID: 19001320 [TBL] [Abstract][Full Text] [Related]
22. Impact of KRAS mutation on outcome of patients with metastatic colorectal cancer. Chang YY; Lin JK; Lin TC; Chen WS; Jeng KJ; Yang SH; Wang HS; Lan YT; Lin CC; Liang WY; Chang SC Hepatogastroenterology; 2014 Oct; 61(135):1946-53. PubMed ID: 25713893 [TBL] [Abstract][Full Text] [Related]
23. KRAS mutations in primary colorectal cancer tumors and related metastases: a potential role in prediction of lung metastasis. Cejas P; López-Gómez M; Aguayo C; Madero R; de Castro Carpeño J; Belda-Iniesta C; Barriuso J; Moreno García V; Larrauri J; López R; Casado E; Gonzalez-Barón M; Feliu J PLoS One; 2009 Dec; 4(12):e8199. PubMed ID: 20020061 [TBL] [Abstract][Full Text] [Related]
24. Identification of EGFR mutation, KRAS mutation, and ALK gene rearrangement in cytological specimens of primary and metastatic lung adenocarcinoma. Cai G; Wong R; Chhieng D; Levy GH; Gettinger SN; Herbst RS; Puchalski JT; Homer RJ; Hui P Cancer Cytopathol; 2013 Sep; 121(9):500-7. PubMed ID: 23495083 [TBL] [Abstract][Full Text] [Related]
25. Comparison of neuroendocrine differentiation and KRAS/NRAS/BRAF/PIK3CA/TP53 mutation status in primary and metastatic colorectal cancer. Kleist B; Kempa M; Novy M; Oberkanins C; Xu L; Li G; Loland C; Poetsch M Int J Clin Exp Pathol; 2014; 7(9):5927-39. PubMed ID: 25337237 [TBL] [Abstract][Full Text] [Related]
27. Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer. Laurent-Puig P; Cayre A; Manceau G; Buc E; Bachet JB; Lecomte T; Rougier P; Lievre A; Landi B; Boige V; Ducreux M; Ychou M; Bibeau F; Bouché O; Reid J; Stone S; Penault-Llorca F J Clin Oncol; 2009 Dec; 27(35):5924-30. PubMed ID: 19884556 [TBL] [Abstract][Full Text] [Related]
28. Influence of KRAS mutation status in metachronous and synchronous metastatic colorectal adenocarcinoma. Rose JS; Serna DS; Martin LK; Li X; Weatherby LM; Abdel-Misih S; Zhao W; Bekaii-Saab T Cancer; 2012 Dec; 118(24):6243-52. PubMed ID: 22674181 [TBL] [Abstract][Full Text] [Related]
29. The impact of KRAS mutations on prognosis in surgically resected colorectal cancer patients with liver and lung metastases: a retrospective analysis. Kim HS; Heo JS; Lee J; Lee JY; Lee MY; Lim SH; Lee WY; Kim SH; Park YA; Cho YB; Yun SH; Kim ST; Park JO; Lim HY; Choi YS; Kwon WI; Kim HC; Park YS BMC Cancer; 2016 Feb; 16():120. PubMed ID: 26887348 [TBL] [Abstract][Full Text] [Related]
30. Acquired KRAS mutations during progression of colorectal cancer metastases: possible implications for therapy and prognosis. Bouchahda M; Karaboué A; Saffroy R; Innominato P; Gorden L; Guettier C; Adam R; Lévi F Cancer Chemother Pharmacol; 2010 Aug; 66(3):605-9. PubMed ID: 20361188 [TBL] [Abstract][Full Text] [Related]
31. miR-181a is associated with poor clinical outcome in patients with colorectal cancer treated with EGFR inhibitor. Pichler M; Winter E; Ress AL; Bauernhofer T; Gerger A; Kiesslich T; Lax S; Samonigg H; Hoefler G J Clin Pathol; 2014 Mar; 67(3):198-203. PubMed ID: 24098024 [TBL] [Abstract][Full Text] [Related]
32. KRAS Status as an Independent Prognostic Factor for Survival after Yttrium-90 Radioembolization Therapy for Unresectable Colorectal Cancer Liver Metastases. Lahti SJ; Xing M; Zhang D; Lee JJ; Magnetta MJ; Kim HS J Vasc Interv Radiol; 2015 Aug; 26(8):1102-11. PubMed ID: 26210240 [TBL] [Abstract][Full Text] [Related]
33. KRAS and BRAF mutation status in circulating colorectal tumor cells and their correlation with primary and metastatic tumor tissue. Mostert B; Jiang Y; Sieuwerts AM; Wang H; Bolt-de Vries J; Biermann K; Kraan J; Lalmahomed Z; van Galen A; de Weerd V; van der Spoel P; Ramírez-Moreno R; Verhoef C; Ijzermans JN; Wang Y; Gratama JW; Foekens JA; Sleijfer S; Martens JW Int J Cancer; 2013 Jul; 133(1):130-41. PubMed ID: 23233388 [TBL] [Abstract][Full Text] [Related]
34. RAS mutation status predicts survival and patterns of recurrence in patients undergoing hepatectomy for colorectal liver metastases. Vauthey JN; Zimmitti G; Kopetz SE; Shindoh J; Chen SS; Andreou A; Curley SA; Aloia TA; Maru DM Ann Surg; 2013 Oct; 258(4):619-26; discussion 626-7. PubMed ID: 24018645 [TBL] [Abstract][Full Text] [Related]
35. Heterogeneity of KRAS status may explain the subset of discordant KRAS status between primary and metastatic colorectal cancer. Watanabe T; Kobunai T; Yamamoto Y; Matsuda K; Ishihara S; Nozawa K; Iinuma H; Shibuya H; Eshima K Dis Colon Rectum; 2011 Sep; 54(9):1170-8. PubMed ID: 21825899 [TBL] [Abstract][Full Text] [Related]
36. KRAS mutant allele-specific imbalance (MASI) assessment in routine samples of patients with metastatic colorectal cancer. Malapelle U; Sgariglia R; De Stefano A; Bellevicine C; Vigliar E; de Biase D; Sepe R; Pallante P; Carlomagno C; Tallini G; Troncone G J Clin Pathol; 2015 Apr; 68(4):265-9. PubMed ID: 25609577 [TBL] [Abstract][Full Text] [Related]
37. Changes in mutational status during third-line treatment for metastatic colorectal cancer--results of consecutive measurement of cell free DNA, KRAS and BRAF in the plasma. Spindler KL; Pallisgaard N; Andersen RF; Jakobsen A Int J Cancer; 2014 Nov; 135(9):2215-22. PubMed ID: 24659028 [TBL] [Abstract][Full Text] [Related]
38. Analysis of KRAS, BRAF, PTEN, IGF1R, EGFR intron 1 CA status in both primary tumors and paired metastases in determining benefit from cetuximab therapy in colon cancer. Park JH; Han SW; Oh DY; Im SA; Jeong SY; Park KJ; Kim TY; Bang YJ; Park JG Cancer Chemother Pharmacol; 2011 Oct; 68(4):1045-55. PubMed ID: 21340604 [TBL] [Abstract][Full Text] [Related]
39. The role of K-RAS and B-RAF mutations as biomarkers in metastatic colorectal cancer. Selcukbiricik F; Erdamar S; Ozkurt CU; Molinas Mandel N; Demirelli F; Ozguroglu M; Tural D; Buyukunal E; Serdengecti S J BUON; 2013; 18(1):116-23. PubMed ID: 23613396 [TBL] [Abstract][Full Text] [Related]
40. Impact of Single-organ Metastasis to the Liver or Lung and Genetic Mutation Status on Prognosis in Stage IV Colorectal Cancer. Cavallaro P; Bordeianou L; Stafford C; Clark J; Berger D; Cusack J; Kunitake H; Francone T; Ricciardi R Clin Colorectal Cancer; 2020 Mar; 19(1):e8-e17. PubMed ID: 31899147 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]